Clinical Trials / Research Studies
Ependymoma Relapse / Refractory

Ependymoma Relapse / Refractory

Showing 11 - 13 of 13 records.

PBTC-059: HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma

  • Ages: 1 Year to 22 Years

This is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells). In addition to looking for side effects, we will study how well this treatment works against a brain tumor called ependymoma that has come ba ...More

PBTC-060: A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

  • Ages: 1 Year to 21 Years

This is a multicenter pilot study of SurVaxM (SVN53-67/M57-KLH) for children and young adults with progressive or relapsed medulloblastoma, high grade glioma, ependymoma and newly diagnosed diffuse intrinsic pontine glioma. Survivin (BIRC5) is an inhibitor of apoptosis (IAP) protein that is highly e ...More

PEPN2111: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Ages: 1 Month to 30 Years

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block sig ...More

Previous Page12Next Page

Contact Us

Contact us.

To learn more about available clinical trials related to brain and spinal tumors, contact us at cancer@cchmc.org or 513-636-2799.

Related Studies

Give Today

3333 Burnet Avenue, Cincinnati, Ohio 45229-3026

© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.

U.S. News & World Report Honor Roll Badge for Top Children's Hospital.Best Places to Work.America's Best Large Employers